623 related articles for article (PubMed ID: 29895599)
1. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Nicolau JC; Henry P; Kedev S; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2018 Jun; 11(6):e006084. PubMed ID: 29895599
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
[TBL] [Abstract][Full Text] [Related]
3. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial.
Ducrocq G; Jolly S; Mehta SR; Rao SV; Patel T; Moreno R; Gao P; Steg PG
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25873729
[TBL] [Abstract][Full Text] [Related]
4. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.
Abtan J; Wiviott SD; Sorbets E; Popovic B; Elbez Y; Mehta SR; Sabatine MS; Bode C; Pollack CV; Cohen M; Moccetti T; Laanmets P; Faxon D; Okreglicki A; Ducrocq G; Steg PG;
Arch Cardiovasc Dis; 2021 Mar; 114(3):187-196. PubMed ID: 33518473
[TBL] [Abstract][Full Text] [Related]
5. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Steg PG; Mehta SR; Pollack CV; Bode C; Gaudin C; Fanouillere K; Moryusef A; Wiviott SD; Sabatine MS
Am Heart J; 2012 Dec; 164(6):817-24.e13. PubMed ID: 23194481
[TBL] [Abstract][Full Text] [Related]
8. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
[TBL] [Abstract][Full Text] [Related]
9. Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial.
Dillinger JG; Ducrocq G; Elbez Y; Cohen M; Bode C; Pollack C; Petrauskiene B; Henry P; Dorobantu M; French WJ; Wiviott SD; Sabatine MS; Mehta SR; Steg PG
Circ Cardiovasc Interv; 2021 Jan; 14(1):e009759. PubMed ID: 33430604
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
[TBL] [Abstract][Full Text] [Related]
11. Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention in acute myocardial infarction: a VALIDATE-SWEDEHEART substudy.
Sharma T; Rylance R; Karlsson S; Koul S; Venetsanos D; Omerovic E; Fröbert O; Persson J; James S; Erlinge D
Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):6-13. PubMed ID: 31093662
[TBL] [Abstract][Full Text] [Related]
12. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
[TBL] [Abstract][Full Text] [Related]
13. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
; Steg PG; Jolly SS; Mehta SR; Afzal R; Xavier D; Rupprecht HJ; López-Sendón JL; Budaj A; Diaz R; Avezum A; Widimsky P; Rao SV; Chrolavicius S; Meeks B; Joyner C; Pogue J; Yusuf S
JAMA; 2010 Sep; 304(12):1339-49. PubMed ID: 20805623
[TBL] [Abstract][Full Text] [Related]
14. Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression.
Mottillo S; Filion KB; Joseph L; Eisenberg MJ
Catheter Cardiovasc Interv; 2017 Feb; 89(3):351-366. PubMed ID: 27545117
[TBL] [Abstract][Full Text] [Related]
15. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
16. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry.
Safley DM; Venkitachalam L; Kennedy KF; Cohen DJ
JACC Cardiovasc Interv; 2015 Oct; 8(12):1574-82. PubMed ID: 26493250
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
Capuano C; Sesana M; Leonzi O; Cuccia C
J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
Huang X; Chen S; Redfors B; Zhang Y; Souza CF; Mehran R; Bansilal S; Kirtane AJ; Brener SJ; Feite F; Dangas GD; Ben-Yehuda O; Stone GW
Coron Artery Dis; 2020 Jan; 31(1):59-65. PubMed ID: 31809479
[TBL] [Abstract][Full Text] [Related]
19. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
[TBL] [Abstract][Full Text] [Related]
20. Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.
Geisler T; Droppa M; Gawaz M; Steinhubl SR; Bertrand ME; Lincoff AM; Cequier AR; Desmet W; Rasmussen LH; Hoekstra JW; Bernstein D; Deliargyris EN; Mehran R; Stone GW
Catheter Cardiovasc Interv; 2016 Aug; 88(2):174-81. PubMed ID: 26332193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
